|
Nurix Therapeutics Inc (NASDAQ: NRIX) |
|
Nurix Therapeutics Inc
NRIX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Nurix Therapeutics Inc growth rates, revenue grew
by 11.26 % in I. Quarter 2025 from the same quarter a year ago.
Ranking at No. 16
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -0.46 %
Nurix Therapeutics Inc net loss increased from $-42 millions, to $-56 millions in I. Quarter 2025,
• More on NRIX's Growth
|
|
Nurix Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 37.01 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 17.12.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on NRIX's Valuation
|
|
|
|
|
Nurix Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 37.01 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 17.12.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
Nurix Therapeutics Inc Price to Book Ratio is at 2.01 lower than Industry Avg. of 79.76. and higher than S&P 500 Avg. of 0.01
• More on NRIX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com